Literature DB >> 21820554

Vaccine development against Trypanosoma cruzi and Chagas disease.

Juan C Vázquez-Chagoyán1, Shivali Gupta, Nisha Jain Garg.   

Abstract

The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21820554     DOI： 10.1016/B978-0-12-385863-4.00006-X

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN： 0065-308X            Impact factor:   3.870


  30 in total

1.  Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Authors:  Marina N Matos; Silvia I Cazorla; Augusto E Bivona; Celina Morales; Carlos A Guzmán; Emilio L Malchiodi
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

2.  A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Authors:  Carylinda Serna; Joshua A Lara; Silas P Rodrigues; Alexandre F Marques; Igor C Almeida; Rosa A Maldonado
Journal:  Vaccine       Date:  2014-04-30       Impact factor: 3.641

3.  Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi.

Authors:  Ernesto S Nakayasu; Tiago J P Sobreira; Rafael Torres; Luciane Ganiko; Paulo S L Oliveira; Alexandre F Marques; Igor C Almeida
Journal:  J Proteome Res       Date:  2011-12-08       Impact factor: 4.466

Review 4.  CD8+ T cells in Trypanosoma cruzi infection.

Authors:  Rick L Tarleton
Journal:  Semin Immunopathol       Date:  2015-04-29       Impact factor: 9.623

5.  Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  Vaccine       Date:  2012-10-15       Impact factor: 3.641

Review 6.  Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects.

Authors:  Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

7.  In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Authors:  Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Marcos Meuser Batista; Beatriz Philot Pavão; Julianna Siciliano Araújo; Claudia Alessandra Fortes Aiub; Patrícia Bernardino da Silva; Jessica Lionel; Constança Britto; Kwangho Kim; Gary Sulikowski; Tatiana Y Hargrove; Michael R Waterman; Galina I Lepesheva
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

8.  Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.

Authors:  Shivali Gupta; Trevor S Silva; Jessica E Osizugbo; Laura Tucker; Heidi M Spratt; Nisha J Garg
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

Review 9.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

Review 10.  Nano-Medicines a Hope for Chagas Disease!

Authors:  Satabdi Datta Choudhury
Journal:  Front Mol Biosci       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.